佩索利成功治疗3名泛发性脓疱型银屑病患者并亚洲患者案例回顾

Successful Treatment of Three Patients with Generalized Pustular Psoriasis and a Retrospective Review of Asian Patient Cases by Spesolimab

摘要: 目的：观察佩索利单抗治疗脓疱型银屑病(GPP)的有效性及安全性。方法：应用佩索利单抗900 mg单次静脉滴注治疗3名中国女性GPP患者，观察其GPPGA评分、GPPASI评分、脓疱消退时间及不良事件，进一步评估临床疗效和安全性。在pubmed及中国知网中检索关键词为“generalized pustular psoriasis”AND“spesolimab”的研究，并对检索到的11名亚洲地区脓疱型银屑病患者进行案例回顾。结果：三名患者接受佩索利单抗治疗后的第6日，整体GPPGA降低了69.6%，GPPGA平均得分1.7分，脓疱平均消退时间为6.7小时。不良反应包括困顿、嗜睡，消化系统不适及头痛等，均表现为轻度。所有14名患者中，在佩索利单抗应用后，83.3%患者的脓疱在第一周内消退，最快12 h小时消退，且所有患者红斑1周内均得到改善。除1位患者外，所有患者在平均4.8月的随访中无复发，且治疗及随访期间发生的不良事件均是轻微的。结论：佩索利单抗对亚洲泛发性脓疱型银屑病患者有效且安全性高。

Abstract: Objective: To observe the efficacy and safety of spesolimab in the treatment of pustular psoriasis (GPP). Method: Three Chinese female patients with GPP were treated with a single intravenous infusion of 900 mg of spesolimab. Their GPPGA score, GPPASI score, and pustule regression time, and adverse events were observed to further evaluate the clinical efficacy. Search for studies using the keywords “generalized pustular psoriasis” and “spesolimab” on PubMed and CNKI, and conduct a case review of 11 patients with pustular psoriasis in Asia. Result: On the 6th day after receiving spesolimab treatment, the overall GPPGA of the three patients decreased by 69.6%, with an average GPPGA score of 1.7 points and an average pustule disappearance time of 6.7 hours. Adverse reactions include drowsiness, drowsiness, digestive system discomfort, and headache, all of which are mild in nature. Among all 14 patients, 83.3% had pustules disappear within the first week after the application of pembrolizumab, with the fastest disappearance occurring within 12 hours, and all patients showed improvement in erythema within one week. Except for one patient, all patients had no recurrence during an average follow-up of 4.8 months, and the adverse events that occurred during treatment and follow-up were mild. Conclusion: Spesolimab is effective and safe for patients with Asian generalized pustular psoriasis.